Enzo Biochem (ENZ) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Enzo Biochem Reports Strong Fourth Quarter Results
October 13, 2015 7:30 AM EDTHigher Revenues and Operating Income, Plus Legal Settlements, Result in Net Income Exceeding $8 Million, or 18 Cents Per Share
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem Inc. (NYSE: ENZ) today reported results for the fiscal quarter and year ended July 31, 2015.
Fourth Quarter Highlights
Revenues of $25.7 million were up 3% over the prior year quarter, despite decreased royalty income. Clinical Labs revenues of $17.2 million were up 11% over the same period in the prior year while Life Sciences product revenues were essentially unchanged on a constant... More